Published in TB and Outbreaks Week, May 23rd, 2000
The researchers, led by R.A. Burger, investigated the effect of oseltamivir, which has been approved as an antiviral agent for use against the influenza virus in humans, on cellular and humoral immunity in virally infected (A/NWS/33 (HINI) and uninfected mice.
Study mice were administered oseltamivir two times a day at a dose of 100 mg/kg/day for five days, according to study protocol. At two hours after oseltamivir...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week